Casdin Partners Master Fund, L.P. bought $659k of LAB
director, owner at STANDARD BIOTOOLS INC.. 525,000 shares at an average of $1.25, traded Aug 22, 2025, filed Aug 26, 2025.
Score components
- +15RoleDirector
- +20Trade size$659k at market
- -5Relative to holdingsUnder 1% of holdings (0.9%)
- +8Price context44% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000919574-25-005152, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 22, 2025 | POpen-market purchase Common Stock, $0.001 par value per shareindirect: See footnote | +200,000 | $1.26 | $253k | 59,950,000 | Aug 26, 2025 |
| Aug 25, 2025 | POpen-market purchase Common Stock, $0.001 par value per shareindirect: See footnote | +200,000 | $1.24 | $248k | 60,150,000 | Aug 26, 2025 |
| Aug 26, 2025 | POpen-market purchase Common Stock, $0.001 par value per shareindirect: See footnote | +125,000 | $1.26 | $158k | 60,275,000 | Aug 26, 2025 |
Related signals
Other insiders at STANDARD BIOTOOLS INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 41Moderate | LABbuy STANDARD BIOTOOLS INC. | Casdin Partners Master Fund, L.P. director, owner | $503k 350,000 shares | +0% | |
| 56Moderate | LABbuy STANDARD BIOTOOLS INC. | Casdin Partners Master Fund, L.P. director, owner | $10M 7,700,000 shares | +12% | |
| 53Moderate | LABbuy STANDARD BIOTOOLS INC. | Casdin Partners Master Fund, L.P. director, owner | $1.4M 1,075,000 shares | +2% | |
| 53Moderate | LABbuy STANDARD BIOTOOLS INC. | Casdin Partners Master Fund, L.P. director, owner | $1.1M 925,000 shares | +1% | |
| 53Moderate | LABbuy STANDARD BIOTOOLS INC. | Casdin Partners Master Fund, L.P. director, owner | $1.4M 1,175,000 shares | +2% | |
| 34Weak | LABbuy STANDARD BIOTOOLS INC. | Casdin Partners Master Fund, L.P. director, owner | $129k 100,000 shares | +0% | |
| 43Moderate | LABbuy STANDARD BIOTOOLS INC. | Casdin Partners Master Fund, L.P. director, owner | $636k 500,000 shares | +1% | |
| 35Weak | LABbuy STANDARD BIOTOOLS INC. | Casdin Partners Master Fund, L.P. director, owner | $443k 358,220 shares | +1% | |
| 40Moderate | STANDARD BIOTOOLS INC. | Michael Egholm President & CEO | $5,150 5,473 shares | -0% | |
| 37Weak | STANDARD BIOTOOLS INC. | Hanjoon Alex Kim Chief Financial Officer | $1,344 1,428 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.